Q-omics provides the consensus-scored GPR160P2 profile across patient tissues and cancer cell-line models. GPR160P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, GPR160P2 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, GPR160P2 RNA expression shows 6,157 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, KIRC, and STAD as cancer lineages where GPR160P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR160P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR160P2 survival associations across molecular data types. GPR160P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR160P2 RNA expression–survival associations across cancer types. High GPR160P2 expression shows unfavorable associations in TGCT, KIRC, KICH and UCS, but favorable associations in ESCA and LUSC. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for GPR160P2 RNA expression.
This table summarizes GPR160P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR160P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR160P2 shows higher tumor expression in KIRC. The KIRC box plot shows higher GPR160P2 RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .039).
This table shows molecular features associated with GPR160P2 in patient tissues and cancer cell lines. In patient samples, GPR160P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
